New Narcolepsy Treatment Available Internationally
The oral medication ORZEYFUL is now available to adults with narcolepsy type 1 to help improve wakefulness.
Updated on Oct. 15, 2026 in Sleep Disorders
Live Poll
Do you believe new pharmaceutical breakthroughs effectively improve the daily quality of life for patients?
Takeda has officially released ORZEYFUL, a new oral medication for the treatment of narcolepsy type 1, in Japan and China. The drug is also scheduled to launch in the United States this coming November.
Why it matters
Narcolepsy type 1 is a chronic condition caused by orexin deficiency, and this new therapy offers a way to manage symptoms. The arrival of this treatment provides a new option for patients seeking to improve wakefulness and reduce cataplexy.
Phase 3 clinical studies conducted over 12 weeks showed that ORZEYFUL significantly improved wakefulness and reduced cataplexy compared to placebo, with p-values of <0.001. Findings remain preliminary regarding long-term safety and efficacy.
The players
Takeda
A global pharmaceutical company that focuses on developing treatments for rare diseases, neuroscience, and gastrointestinal health.
The details
ORZEYFUL is an oral orexin receptor 2 agonist that works by stimulating these receptors to restore necessary orexin signaling in the brain. Patients should be aware that common side effects reported during trials include insomnia, urinary urgency, urinary frequency, and excessive saliva. The treatment is currently indicated for those aged 16 and older in China.
Timeline
June 14-17, 2026: Phase 3 trial results were presented at SLEEP 2026.
October 15, 2026: Takeda announced the availability of ORZEYFUL.
November 2026: ORZEYFUL is scheduled for launch in the U.S.
Health Landscape
The introduction of ORZEYFUL follows the standard trajectory of therapies presented at clinical research forums like SLEEP 2026. This launch marks a new approach in addressing the underlying orexin signaling deficiency characteristic of narcolepsy type 1.
Patients with narcolepsy type 1 should consult their physician to discuss whether this new orexin receptor agonist is an appropriate consideration for their treatment plan. Be prepared to monitor for common side effects such as urinary urgency or insomnia if a treatment change is considered.
The takeaway
ORZEYFUL represents a new therapeutic option targeting the biological roots of narcolepsy type 1. Patients should maintain a log of symptom patterns and potential side effects to facilitate an informed discussion with their healthcare provider.
What happens next
The launch of ORZEYFUL is scheduled to occur in the United States in November 2026.
Further reading
For more information on managing chronic sleep conditions, visit our section on Sleep Disorders.
More information
For more information, visit the Takeda company website.
Live Poll
Do you believe new pharmaceutical breakthroughs effectively improve the daily quality of life for patients?
